blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3478322

EP3478322 - METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  27.11.2020
Database last updated on 15.06.2024
FormerGrant of patent is intended
Status updated on  21.04.2020
FormerRequest for examination was made
Status updated on  05.04.2019
FormerThe international publication has been made
Status updated on  12.01.2018
Formerunknown
Status updated on  18.07.2017
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024 [2024/29]
Applicant(s)For all designated states
Poolbeg Pharma (UK) Limited
Queen Mary Bioenterprises Innovation Centre
42 New Road
London E1 2AX / GB
[2023/36]
Former [2021/22]For all designated states
Orph Pharma IP Company Limited
Queen Mary Bioenterprises Innovation Centre
42 New Road
London
E1 2AX / GB
Former [2019/19]For all designated states
hVIVO Services Limited
Queen Mary Bioenterprises Innovation Centre
42 New Road
London
E1 2AX / GB
Inventor(s)01 / WHITTAKER, Paul, Andrew
c/o hVIVO Services Limited
Biopark
Broadwater Road
Welwyn Garden City
Hertfordshire Hertfordshire AL7 3AX / GB
02 / TORBETT, Neil, Edward
c/o hVIVO Services Limited
Biopark
BroadwaterRoad
Welwyn Garden City
Hertfordshire Hertfordshire AL7 3AX / GB
 [2019/19]
Representative(s)Abel & Imray LLP
Westpoint Building
James Street West
Bath BA1 2DA / GB
[N/P]
Former [2019/19]Abel & Imray
Westpoint Building
James Street West
Bath BA1 2DA / GB
Application number, filing date17736709.126.06.2017
[2019/19]
WO2017GB51865
Priority number, dateGB2016001171202.07.2016         Original published format: GB 201611712
[2019/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018007788
Date:11.01.2018
Language:EN
[2018/02]
Type: A1 Application with search report 
No.:EP3478322
Date:08.05.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 11.01.2018 takes the place of the publication of the European patent application.
[2019/19]
Type: B1 Patent specification 
No.:EP3478322
Date:30.12.2020
Language:EN
[2020/53]
Search report(s)International search report - published on:EP11.01.2018
ClassificationIPC:A61K45/00, A61K31/395, A61P31/12
[2019/19]
CPC:
A61K31/395 (EP); C07K16/1018 (US); A61K38/005 (US);
A61K38/191 (US); A61K38/204 (US); A61K38/2066 (US);
A61P31/16 (EP); C12N9/12 (US); C12Y207/11024 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/19]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERFAHREN UND VERBINDUNGEN ZUR BEHANDLUNG ODER PRÄVENTION VON SCHWERER INFLUENZA[2019/19]
English:METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA[2019/19]
French:MÉTHODES ET COMPOSÉS POUR LE TRAITEMENT OU LA PRÉVENTION DE FORMES GRAVES DE LA GRIPPE[2019/19]
Entry into regional phase15.01.2019National basic fee paid 
15.01.2019Designation fee(s) paid 
15.01.2019Examination fee paid 
Examination procedure15.01.2019Examination requested  [2019/19]
15.01.2019Date on which the examining division has become responsible
16.08.2019Amendment by applicant (claims and/or description)
22.04.2020Communication of intention to grant the patent
21.09.2020Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
17.11.2020Fee for grant paid
17.11.2020Fee for publishing/printing paid
17.11.2020Receipt of the translation of the claim(s)
Opposition(s)Opponent(s)01  30.09.2021  19.09.2023  WITHDRAWN
Gill Jennings & Every LLP
The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
Opponent's representative
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 [2023/43]
Former [2023/17]
Opponent(s)01  30.09.2021  06.10.2021  ADMISSIBLE
Gill Jennings & Every LLP
The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
Opponent's representative
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Former [2021/45]
Opponent(s)01  30.09.2021  06.10.2021  ADMISSIBLE
Gill Jennings & Every LLP
The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
Opponent's representative
Gill Jennings & Every LLP
The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
15.10.2021Invitation to proprietor to file observations on the notice of opposition
25.04.2022Reply of patent proprietor to notice(s) of opposition
27.09.2023Cancellation of oral proceeding that was planned for 21.11.2023
28.09.2023Despatch of communication that the opposition procedure will be closed
08.10.2023Legal effect of closure of opposition procedure [2024/07]
21.11.2023Date of oral proceedings
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
17.11.2020Request for further processing filed
17.11.2020Full payment received (date of receipt of payment)
Request granted
24.11.2020Decision despatched
Fees paidRenewal fee
13.06.2019Renewal fee patent year 03
31.03.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.06.2017
AL30.12.2020
AT30.12.2020
CY30.12.2020
CZ30.12.2020
DK30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
MC30.12.2020
MK30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SI30.12.2020
SK30.12.2020
SM30.12.2020
TR30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
IS30.04.2021
PT30.04.2021
LU26.06.2021
BE30.06.2021
[2024/29]
Former [2024/22]HU26.06.2017
AL30.12.2020
AT30.12.2020
CY30.12.2020
CZ30.12.2020
DK30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
MC30.12.2020
MK30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SI30.12.2020
SK30.12.2020
SM30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
IS30.04.2021
PT30.04.2021
LU26.06.2021
BE30.06.2021
Former [2023/33]HU26.06.2017
AL30.12.2020
AT30.12.2020
CY30.12.2020
CZ30.12.2020
DK30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
MC30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SI30.12.2020
SK30.12.2020
SM30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
IS30.04.2021
PT30.04.2021
LU26.06.2021
BE30.06.2021
Former [2023/30]AL30.12.2020
AT30.12.2020
CY30.12.2020
CZ30.12.2020
DK30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
MC30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SI30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
IS30.04.2021
PT30.04.2021
LU26.06.2021
BE30.06.2021
Former [2022/34]AL30.12.2020
AT30.12.2020
CZ30.12.2020
DK30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
MC30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SI30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
IS30.04.2021
PT30.04.2021
LU26.06.2021
BE30.06.2021
Former [2022/23]AL30.12.2020
AT30.12.2020
CZ30.12.2020
DK30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
MC30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SI30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
IS30.04.2021
PT30.04.2021
LU26.06.2021
Former [2022/18]AL30.12.2020
AT30.12.2020
CZ30.12.2020
DK30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
MC30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SI30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
PT30.04.2021
LU26.06.2021
IS22.12.2021
Former [2022/13]AL30.12.2020
AT30.12.2020
CZ30.12.2020
DK30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
MC30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SI30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
PT30.04.2021
IS22.12.2021
Former [2022/10]AL30.12.2020
AT30.12.2020
CZ30.12.2020
DK30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
MC30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
PT30.04.2021
IS22.12.2021
Former [2022/08]AL30.12.2020
AT30.12.2020
CZ30.12.2020
DK30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
MC30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
IS30.04.2021
PT30.04.2021
Former [2021/49]AL30.12.2020
AT30.12.2020
CZ30.12.2020
DK30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
IS30.04.2021
PT30.04.2021
Former [2021/45]AL30.12.2020
AT30.12.2020
CZ30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
IS30.04.2021
PT30.04.2021
Former [2021/42]AT30.12.2020
CZ30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
IS30.04.2021
PT30.04.2021
Former [2021/39]AT30.12.2020
CZ30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
PL30.12.2020
RO30.12.2020
RS30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
PT30.04.2021
Former [2021/37]AT30.12.2020
CZ30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
RO30.12.2020
RS30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
PT30.04.2021
Former [2021/36]CZ30.12.2020
EE30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
RO30.12.2020
RS30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
PT30.04.2021
Former [2021/35]CZ30.12.2020
FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
RO30.12.2020
RS30.12.2020
SK30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
PT30.04.2021
Former [2021/33]FI30.12.2020
HR30.12.2020
LT30.12.2020
LV30.12.2020
RS30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
PT30.04.2021
Former [2021/28]FI30.12.2020
HR30.12.2020
LV30.12.2020
RS30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
Former [2021/23]FI30.12.2020
LV30.12.2020
RS30.12.2020
BG30.03.2021
NO30.03.2021
GR31.03.2021
Former [2021/22]FI30.12.2020
RS30.12.2020
NO30.03.2021
Former [2021/20]FI30.12.2020
Cited inInternational search[I]WO2015173788  (UNIV MUENSTER WILHELMS [DE]) [I] 1-33 * page 3, lines 20-25 * * page 23, lines 17-26 ** page 28, line 9 *;
 [X]  - Y. BORGELING ET AL, "Inhibition of p38 Mitogen-activated Protein Kinase Impairs Influenza Virus-induced Primary and Secondary Host Gene Responses and Protects Mice from Lethal H5N1 Infection", JOURNAL OF BIOLOGICAL CHEMISTRY, (20131104), vol. 289, no. 1, doi:10.1074/jbc.M113.469239, ISSN 0021-9258, pages 13 - 27, XP055161048 [X] 1-33 * page 23; figure 7 *

DOI:   http://dx.doi.org/10.1074/jbc.M113.469239
OppositionWO0119322
 WO2015173788
    - BORGELING et al., "Inhibition of p38 Mitogen-activated Protein Kinase Impairs Influenza Virus-induced Primary and Secondary Host Gene Responses and Protects Mice from Lethal H5N1 Infection", The Journal of Biological Chemistry, (20131104), pages 13 - 27, XP055161048

DOI:   http://dx.doi.org/10.1074/jbc.M113.469239
    - CUENDA et al., "p38 MAP-Kinases pathway regulation, function and role in human diseases", Biochimica et Biophysica Acta, (20070324), XP022181685

DOI:   http://dx.doi.org/10.1016/j.bbamcr.2007.03.010
    - LEE et al., "p38 Mitogen-Activated Protein Kinase-Dependent Hyperinduction of Tumor Necrosis Factor Alpha Expression in Response to Avian Influenza Virus H5N1", Journal of Virology, (20050800), vol. 79, no. 16, XP055577642

DOI:   http://dx.doi.org/10.1128/JVI.79.16.10147-10154.2005
    - GEILER et al., "Comparison of pro-inflammatory cytokine expression and cellular signal transduction in human macrophages infected with different influenza A viruses", Med Microbiol Immunol, (20100924), vol. 200, pages 53 - 60, XP019873149

DOI:   http://dx.doi.org/10.1007/s00430-010-0173-y
    - HUI et al., "Induction of Proinflammatory Cytokines in Primary Human Macrophages by Influenza A Virus (H5N1) Is Selectively Regulated by IFN Regulatory Factor 3 and p38 MAPK", The Journal of Immunology, (20090115), pages 1088 - 1098, XP055849642
    - GEILER et al., "N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus", Biochemical Pharmacology, (20090902), vol. 79, pages 413 - 420, XP026776992

DOI:   http://dx.doi.org/10.1016/j.bcp.2009.08.025
    - WU et al., "Innate immune response to H3N2 and H1N1 influenza virus infection in a human lung organ culture model", Virology, (20100120), pages 178 - 188, XP055849645
    - WEI et al., "Roles of p38 MAPK in the regulation of the inflammatory response to swine influenza virus-induced acute lung injury in mice", Acta virologica, (20140000), XP055577637

DOI:   http://dx.doi.org/10.4149/av_2014_04_374
    - LIU et al., "Mouse lung slices: An ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses", Antiviral Research, (20150526), vol. 120, pages 101 - 111, XP055355559

DOI:   http://dx.doi.org/10.1016/j.antiviral.2015.05.008
    - CHOI et al., "A novel p38 mitogen activated protein kinase (MAPK) specific inhibitor suppresses respiratory syncytial virus and influenza A virus replication by inhibiting virus-induced p38 MAPK activation", Biochemical and Biophysical Research Communications, (20160623), vol. 477, XP029641769

DOI:   http://dx.doi.org/10.1016/j.bbrc.2016.06.111
    - PAQUETTE et al., "Interleukin-6 Is a Potential Biomarker for Severe Pandemic H1N1 Influenza A Infection", PLoS ONE, (20120605), vol. 7, no. 6, XP055849658
    - RAMOS et al., "Modulating the innate immune response to influenza A virus: potential therapeutic use of anti-inflammatory drugs", Frontiers in Immunology, (20150720), vol. 6, XP055849664
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.